Effect of erythropoietin on human tumor growth in xenograft models

Molecular Medicine Reports

Volumn 3, Issue 1, 2010, Pages 95-101

  Kataoka, Motoyuki ^a   Moriya, Yoichiro ^a   Moriguchi, Yoshiyuki ^a   Iwai, Toshiki ^a   Fujimoto Ouchi, Kaori ^a   Shirane, Masatoshi ^a   Kondoh, Kumiko ^a   Mori, Kazushige ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bevacizumab; Epoetin ; Erythropoietin receptor; Human cancer xenograft

Indexed keywords

BEVACIZUMAB; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 76149088759     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr-00000224     Document Type: Article

References (40)

1. Jelkmann W: Erythropoietin: structure, control of production and function. Physiol Rev 72: 449-489, 1992.
2. Lacombe C and Mayeux P: The molecular biology of erythropoietin. Nephrol Dial Transplant 14: 22-28, 1999.
3. Tilbrook PA and Klinken SP: Erythropoietin and erythropoietin receptor. Growth Fancors 17: 25-35, 1999.
4. D'Andrea AD and Zon LI: Erythropoietin receptor. Subunit structure and activation. J Clin Invest 86: 681-687, 1990.
5. Ng T, Marx G, Littlewood T and Macdougall I: Recombinant erythropoietin in clinical practice. Postgrad Med J 79: 367-376, 2003.
6. Demetri GD, Kris M, Wade J, Degos L and Cella D: Quality-of-life benefit in chemotherapy patients treated with epoeitin α is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412-3425, 1998.
7. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E and Rapoport B: Effect of epoeitin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of randomized, double-controlled trial. J Clin Oncol 19: 2865-2874, 2001.
8. Vansteenkiste J, Pirker R, Massuti B, et al: Aranesp 980297 study group: Double-blind placebo-controlled, randomized phase III trial of darbepoietin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211-1220, 2002.
9. Osterborg A, Brandberg Y, Molostava V, Losava G, Abdulkadyrov K, Hedenus M and Messinger D: Epoetin beta Hematorogy Study Group: randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486-2494, 2002.
10. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083-4107, 2002.
11. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E and Einhorn LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-time-weekly dosing. J Clin Oncol 19: 2875-2882, 2001.
12. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C and Engert A: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489-498, 2005.
13. Glaser CM, Millesi W, Kornek GV, et al: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Rad Oncol Biol Phys 50: 705-715, 2001.
14. Henke M, Laszig R Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003.
15. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoeitin α in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972, 2005.
16. Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer with disease-related anemia. J Clin Oncol 25: 1027-1032, 2007.
17. Rizzo JD, Somerfield MR, Hagerty KL, et al: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111: 25-41, 2008.
18. Juneja V, Keegan P, Gootenberg JE, et al: Continuing Reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 14: 3242-3247, 2008.
19. D'Andrea AD and Zon LI: Erythropoietin receptor: subunit structure and activation. J Clin Invest 86: 681-687, 1990.
20. Farrell F and Lee A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9: 18-30, 2004.
21. Jelkmann W and Wangner K: Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 83: 673-686, 2004.
22. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N and Noguchi CT: Erythropoietin receptor mRNA expression in human endotherial cells. Proc Natl Acad Sci USA 91: 3974-3978, 1994.
23. Wu H, Lee SH, Gao J, Liu X and Iruela-Arispe ML: Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126: 3597-3605, 1999.
24. Arcasoy MO, Amin K, Kanyal AF, Chou SC, Raleigh JA, Varia MA and Haroon ZA: Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82: 911-918, 2002.
25. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K and Verma A: Erythropoietin and erythropoietin receptor expression in human cancet. Cancer Res 61: 3561-3565, 2001.
26. Yasuda Y, Fujita Y, Matsuno T, et al: Erythropoietin regulates tumor growth of human malignancies. Carcinogenesis 24: 1021-1029, 2003.
27. Westenfelder C and Baranowski RL: Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-657, 2000.
28. Arcasoy MO, Jiang X and Haroon ZA: Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 362: 999-1007, 2003.
29. Arcasoy MO, Amin K, Vollmer RT, Jiang X, Demark-Wahnefried W and Haroon ZA: Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 18: 421-430, 2005.
30. Selzer E, Wacheck V, Kodym R, Schlabauer-Wadl H, Schlegel W, Pehamberger H and Jansen B: Erythropoietin receptor expression in human melanoma cells. Melanoma Res 10: 421-426, 2000.
31. Rosti V, Pedrazzoli P, Ponchio L, Zibera C, NovellaA, Lucotti C, Della Cuna GR and Cazzola M: Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 78: 208-212, 1993.
32. Sugawa M and Fukui H: Effects of recombinant human erythropoietin on the growth of various human tumor cells. Biotherapy 19: 181-196, 2005.
33. Tovari J, Gilly R, Raso E, Paku S, Bereczky B, Varga N, Vago A and Timar J: Recombinant human erythropoietin α targets intratumoral blood vessel, improving chemotherapy in human xenograft models. Cancer Res 65: 7186-7193, 2005.
34. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A and Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5: 347-355, 2006.
35. Silver DF and Piver MS: Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 73: 280-284, 1999.
36. Mittelman M, Nemann D, Peled A, Kanter P and Haran-Ghera N: erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 98: 5181-5186, 2001.
37. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K and Arai H: Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10: 932-939, 2008.
38. Tas F, Eralp Y, Basaran M, et al: Anemia in oncology practice: Relation to diseases and their therapies. Am J Clin Oncol 25: 371-379, 2002.
39. Hardee ME, Cao Y, Fu P, et al: Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2: e549, 2007.
40. Eskens FA and Sleijfer S: The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit. Eur J Cancer 44: 2350-2356, 2008.